Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other Working Capital Changes (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Other Working Capital Changes for 13 consecutive years, with $808000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes rose 3.99% to $808000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $95000.0, a 111.11% increase, with the full-year FY2025 number at $95000.0, up 111.11% from a year prior.
  • Other Working Capital Changes was $808000.0 for Q4 2025 at Niagen Bioscience, up from -$233000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $808000.0 in Q4 2025 to a low of -$732000.0 in Q3 2024.
  • A 5-year average of -$46250.0 and a median of -$67000.0 in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: tumbled 1736.36% in 2021, then surged 1295.38% in 2024.
  • Niagen Bioscience's Other Working Capital Changes stood at -$69000.0 in 2021, then soared by 263.77% to $113000.0 in 2022, then plummeted by 157.52% to -$65000.0 in 2023, then soared by 1295.38% to $777000.0 in 2024, then rose by 3.99% to $808000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Other Working Capital Changes are $808000.0 (Q4 2025), -$233000.0 (Q3 2025), and -$75000.0 (Q2 2025).